CSIMarket
 
Mirum Pharmaceuticals Inc   (MIRM)
Other Ticker:  
 
 
Price: $26.7700 $-1.40 -4.970%
Day's High: $28.52 Week Perf: -0.63 %
Day's Low: $ 26.69 30 Day Perf: -5.97 %
Volume (M): 2,324 52 Wk High: $ 35.56
Volume (M$): $ 62,200 52 Wk Avg: $27.82
Open: $28.00 52 Wk Low: $21.84



 Market Capitalization (Millions $) 1,100
 Shares Outstanding (Millions) 41
 Employees -
 Revenues (TTM) (Millions $) 145
 Net Income (TTM) (Millions $) -164
 Cash Flow (TTM) (Millions $) 167
 Capital Exp. (TTM) (Millions $) 15

Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for patients with rare liver diseases. The company is dedicated to improving the lives of patients by advancing innovative treatments that address unmet medical needs. Mirum Pharmaceuticals is known for its expertise in developing therapies that target rare diseases like Alagille syndrome, progressive familial intrahepatic cholestasis, and bile acid synthesis disorders. The company aims to provide effective and safe treatments for patients suffering from these rare liver diseases, ultimately improving their quality of life.


   Company Address: 950 Tower Lane, Suite 1050, Foster City 94404 CA
   Company Phone Number: 667-4085   Stock Exchange / Ticker: NASDAQ MIRM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc Reveals Impressive Financial Performance: Loss per Share Reduced by Over 40%

Mirum Pharmaceuticals Inc, a leading player in the Major Pharmaceutical Preparations industry, has recently released its financial results for the third quarter of 2023. The company has managed to significantly reduce its loss per share compared to the previous year, showing positive progress. The loss per share decreased from $-1.02 to $-0.57.
Furthermore, the company has shown improvement in earnings per share, which improved from $-1.94 per share in the prior quarter. This indicates that Mirum Pharmaceuticals Inc's financial performance is heading in the right direction.

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc Narrows Net Loss to -$30.13 Million, Showing Improve from Last Year's Figures

Mirum Pharmaceuticals Inc Reports -$129 Million Cumulative Net Loss in 12 Months Ending in First Quarter 2023
In the 12 months ending in the first quarter of 2023, Mirum Pharmaceuticals Inc registered a cumulative net loss of -$129 million, leading to a negative return on equity (ROE) of -91.76%. Although the company's revenue has increased by 145.098% to $31.6 million from $12.89 million in the corresponding financial reporting period a year ago, 60 other companies in the Major Pharmaceutical Preparations industry achieved a higher return on equity.
For the financial period ending on March 31, 2023, Mirum Pharmaceuticals Inc reported a net loss of -$30.13 million. This is an improvement from the -$36.606 million net loss recorded in the corresponding financial reporting period a year ago. The company's loss per share also decreased from -$1.17 per share to -$0.80 per share, and EPS improved from -$0.87 per share from the previous financial reporting period.






 

Mirum Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com